Abstract
Angiogenesis refers to the formation of recent blood vessels, which is one of the characteristics of cancer progression and it has been deliberated as a putative target to the treatment of many kinds of cancers. The VEGF signaling substrate is very important for angiogenesis and is commonly high-regulated in tumors. As a result, this molecule has attracted the attention of most of the researchers to develop antiangiogenic therapies. We have presented that VEGF blockage in neoadjuvant setting via bevacizumab, aflibercept and sunitinib not only has revealed some promising benefits but also has shown a large negative outcome in the adjuvant trials. However, at an advanced stage of tumors, suppression of VEGF alone is inadequate to stop advancement, encouraging drug resistance, and probably enhancing metastasis and invasion in the tumor microenvironment, thereby suggesting the therapeutic potential of targeting angiogenic pathways in gastrointestinal cancers.
Keywords: angiogenesis, vascular endothelial growth factor, bevacizumab, blood vessels, cancers, antiangiogenic therapies.
Current Pharmaceutical Design
Title:miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers
Volume: 24 Issue: 39
Author(s): Forouzan Amerizadeh, Majid Khazaei, Mona Maftouh, Ramin Mardani and Afsane Bahrami*
Affiliation:
- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand,Iran
Keywords: angiogenesis, vascular endothelial growth factor, bevacizumab, blood vessels, cancers, antiangiogenic therapies.
Abstract: Angiogenesis refers to the formation of recent blood vessels, which is one of the characteristics of cancer progression and it has been deliberated as a putative target to the treatment of many kinds of cancers. The VEGF signaling substrate is very important for angiogenesis and is commonly high-regulated in tumors. As a result, this molecule has attracted the attention of most of the researchers to develop antiangiogenic therapies. We have presented that VEGF blockage in neoadjuvant setting via bevacizumab, aflibercept and sunitinib not only has revealed some promising benefits but also has shown a large negative outcome in the adjuvant trials. However, at an advanced stage of tumors, suppression of VEGF alone is inadequate to stop advancement, encouraging drug resistance, and probably enhancing metastasis and invasion in the tumor microenvironment, thereby suggesting the therapeutic potential of targeting angiogenic pathways in gastrointestinal cancers.
Export Options
About this article
Cite this article as:
Amerizadeh Forouzan , Khazaei Majid , Maftouh Mona , Mardani Ramin and Bahrami Afsane *, miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110161843
DOI https://dx.doi.org/10.2174/1381612825666190110161843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Synthesis of Oleanolic Acid Analogues and Their Cytotoxic Effects on 3T3 Cell Line
Medicinal Chemistry Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
Current Cancer Drug Targets Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Anatomical, Biochemical and Physiological Considerations of the Colon in Design and Development of Novel Drug Delivery Systems
Current Drug Delivery Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element
Anti-Cancer Agents in Medicinal Chemistry Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Recent Advances in Metabolomics
Current Metabolomics Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry